PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
Pharmaceutical Product Development (PPD) is on the hunt for newfangled drugs. One of the world's largest contract research organizations (CROs), PPD provides global research and development services to pharmaceutical, biotech, and medical device companies seeking regulatory approval for their products. The CRO offers a broad range of services, from toxicology testing in the earliest phases of drug research, to the management of large, multi-site clinical trials in which drug compounds are tested on human subjects. Its customers have included most of the world's top 50 pharma companies. PPD was acquired in 2011 for some $3.9 billion by private investors The Carlyle Group and Hellman & Friedman.
929 North Front Street
Wilmington, NC 28401